According to the Hualan vaccine announcement, the company recently received the “Drug Clinical Trial Approval Notice” for the novel influenza virus mRNA vaccine approved and issued by the State Drug Administration, and agreed to carry out clinical trials to prevent influenza caused by vaccine-related influenza viruses. The vaccine is a new class 1.2 drug for prophylactic biological products. The company is the first domestic company to obtain implied approval for clinical trials of this product. Currently, the product is still in need of clinical trials, and there is uncertainty about whether it will be approved for marketing in the future and when it will be approved.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.